Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2022

View Archived Issues

RBD-PB6 RNA aptamer blocks SARS-CoV-2 entry into host cells

Antibodies against SIRPA and SIRPB1 promote antitumoral effect in preclinical study

Icahn School of Medicine at Mount Sinai patents DYRK1A inhibitors

Medshine Discovery divulges new GTPase KRAS G12C mutant inhibitors

X4 Pharmaceuticals presents new CXCR4 antagonists

Gilead Sciences synthesizes new HIV antivirals

Sage Therapeutics discloses new GABA-A receptor modulators

Everest Medicines licenses global rights to EDDC's 3CL protease inhibitors to treat COVID-19

Researchers develop a novel murine model of Cockayne syndrome

HGF mimetic CM-1021 stimulates liver growth in mice

[225Ac]OTSA-101 confers complete remission in preclinical model of synovial sarcoma

Study brings clarity on how MS starts, although not yet why

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...